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Background: Vertical HIV programs have achieved good results
but may not be feasible or appropriate in many resource-limited
settings. Médecins sans Frontières has treated HIV in vertical pro-
grams since 2000 and over time integrated HIV treatment into gen-
eral health care services using simpliﬁed protocols. We analyzed the
survival probability among patients receiving antiretroviral therapy
(ART) from 2003 to 2010 in integrated versus vertical programs in
9 countries in sub-Saharan Africa.
Methods and Findings: Cox regression assessed mortality and
program design association, adjusting for baseline age, body mass
index, clinical WHO stage, tuberculosis, program age and setting.
The analysis included 15,403 HIV-positive adults on ART in
7 vertical (14,124 patients) and 10 integrated (1279 patients)
programs. Cox regression including 14,523 patients followed for
up to 30 months ART showed similar outcomes for mortality
(adjusted hazard ratio (aHR) 1.02; 95% conﬁdence interval (CI):
0.83 to 1.24) and lower risk of loss to follow-up (aHR: 0.71; 95% CI:
0.61 to 0.83) in integrated compared with vertical programs. The
greatest risk of death was from initiating ART at WHO stage 4 (aHR
1.99, 95% CI: 1.74 to 2.29), although greater program experience
was protective (aHR: 0.77, 95% CI: 0.66 to 0.89). Risk of loss to
follow-up was greater in experienced programs (aHR: 3.33; 95% CI:
2.92 to 3.79) and rural settings (aHR: 3.82; 95% CI: 3.49 to 4.20).
Conclusions: ART delivery in integrated general health care
programs results in good outcomes. Compared with vertical HIV
programs, patients initiated ART in integrated programs at more
advanced stages of clinical immunosuppression yet had similar risk
of death and lower risk of loss to follow-up.
Key Words: antiretroviral therapy, HIV, integrated healthcare,
resource-limited settings
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INTRODUCTION
Rapid progress has been made in scaling-up access
to antiretroviral therapy (ART) in resource-limited settings
and early outcomes on treatment are comparable to Western
settings.
1 These early results were predominantly achieved via
large-scale, vertical treatment programs, mainly in urban
areas. Due to substantial resource requirements, vertical pro-
grams may not be feasible or appropriate in rural areas or in
low HIV prevalence areas where other important health pri-
orities place competing demands on health services. Programs
which integrate HIV care into other medical activities offer
a potentially feasible alternative model of introducing HIV
care that can utilize HIV resources and staff to provide both
HIV and non-HIV services.
2,3
Integrated HIV programs have a number of potential
advantages which include the following: increasing the access
of patients to HIV care in areas where vertical HIV programs
may not be feasible; supporting retention in care by bringing
services closer to patients and distributing the burden of HIV
care provision across services
4; strengthening other parts
of health programs by utilizing the increased resources that
HIV usually brings such as clinical training for health staff,
improved laboratory services, and procurement supply manage-
ment systems
5; normalizing HIV as one illness among many,
with potential stigma reduction; allowing the treatment of
patients for multiple conditions in the same facility by the same
staff
6; increasing program cohesiveness; and increasing staff
morale by enabling the treatment of patients dying of HIV.
Despite these potential beneﬁts, integrating HIV care
could come at the expense of the quality of care that can be
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ices and specialized staff. In this study, we assessed outcomes
of patients treated with ART in Médecins sans Frontières
(MSF) integrated and vertical HIV programs.
METHODS
Study Setting
We analyzed retrospective observational cohort data from
17 programs in 9 countries in sub-Saharan Africa (see Map, Sup-
plemental Digital Content 1, http://links.lww.com/QAI/A240).
All sites in sub-Saharan Africa where MSF-Holland com-
menced HIV care from 2003 until 2007 and which maintained
electronic medical records were included. Vertical programs
were deﬁned as those programs designed to speciﬁcally treat
HIV in a population and thus focused only or predominantly
on HIV. Integrated programs aimed to provide comprehen-
sive health care, with inclusion of HIV care as part of the
general health care services provided. Hence there were some
differences in program design and activities between these
models (Table 1). Despite the differences, HIV and opportu-
nistic infection testing, diagnosis and treatment protocols,
adherence counseling and patient follow-up, data collection
and monitoring, laboratory protocols, and drug procurement
and supply mechanisms were standardized across MSF verti-
cal and integrated programs. In addition, out-of-program
training and advisory staff were the same for integrated and
vertical programs. All programs were integrated within the
local Ministry of Health facilities, although drugs and materi-
als were procured and supplied through MSF channels.
Vertical programs were implemented in all projects
opened before 2005. Using the experience gained in these
early vertical programs, MSF began to integrate HIV care into
the general package of services provided in its health
programs. HIV vertical programs were reserved for settings
where HIV was judged to be the major morbidity and an
unmet medical need, but where other basic health needs were
already met by others.
Data Management and Analysis
Data were routinely collected by clinical staff at each
consultation using standardized forms and entered into a
standardized electronic database (Follow-Up and Care of HIV
Infection and AIDS, Epicentre, Paris) maintained at each
program site. Data were included only for the period that
MSF staff were active in the clinics, with ART commence-
ment dates ranging from 2003 until early 2010. Only patients
aged 15 years or older at the time of commencing ART who
had at least 6 months of potential follow-up time were
included in the 12 month analysis. Loss to follow-up was
deﬁned as missing a scheduled appointment by 2 months or
more. Data were censored at time of analysis, death, or at the
last appointment for patients who transferred out of a program
or were lost to follow-up.
Patient data were exported from Follow-Up and Care of
HIV Infection and AIDS according to time on ART cohorts
and analyzed using Microsoft Ofﬁce Excel 2007 and STATA
10.0 and 11.0 (StataCorp, College Station, TX). Patients were
categorized according to the program design (integrated or
vertical). Baseline characteristics were described using
medians and interquartile range for continuous variables
TABLE 1. Comparison of Program Design
Design and Activities Integrated Vertical
Staff responsibilities HIV component only part of an individual’s workload. Doctors caring
for patients with HIV would also work in other areas including
general inpatient wards, maternity, and TB services; HIV counselors
often worked in psychosocial counseling or had other professional
backgrounds such as nursing where they spent the majority of their
time; and nurses worked on general medical wards
Activities involved management of
HIV-positive patients only
Provision of clinical care Doctors, nurses. Task shifting utilized Doctors, nurses. Task shifting utilized
IEC activities Minor component—focus on health staff, patients and their families Large component—attempt to reach the
entire community or target population
HIV testing and counselling Focused on patients presenting to health facilities in ‘patient-initiated’ model Included additional community outreach
component in a ‘client-initiated’ model
Treatment of Opportunistic
infections (OIs)
Treatment for basic OIs and more basic regimens (eg, cotrimoxazole for
toxoplasmosis, ﬂuconazole for cryptococcal meningitis)
Increased availability of OI treatment (eg,
pyrimethamine for toxoplasmosis,
amphotericin B for cryptococcal
meningitis, bleomycin for Kaposi
sarcoma)
TB Care provided by staff involved in HIV activities Patients referred to TB staff for care*
ART Limited availability of second-line ARVs Increased availability second-line ARVs
Diagnostics Limited availability of CD4, viral load, X-ray and ALT Increased availability of CD4, viral load,
X-ray, and ALT
Socioeconomic support programs Not included Included
*Except for Bukavu, Epworth, and Gweru.
ALT, Alanine aminotransferase; ARV, antiretroviral.
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acteristics were compared between program designs on
univariate analysis using Wilcoxon rank sum test for medians
of continuous variables and risk ratios with 95% conﬁdence
intervals (CIs) for binomial variables.
A multivariate Cox proportional hazards model was
used to estimate hazard ratios for the outcome of death,
adjusting for the following potential confounders identiﬁed
a priori: sex (male or female), age at baseline, body mass
index at baseline, WHO stage at baseline (stage 4, stage 1–3),
tuberculosis (TB) at initiation, age of program at the time
the patient commenced ART (providing ART 12 months or
more, providing ART less than 12 months), and setting
(rural, urban). CD4 at initiation, although important, was
not included due to relatively large amounts (30%) of missing
data because not all programs were able to provide CD4
testing at all times. Only patients with all data available were
included in the multivariable model. ART experience before
initiation with MSF (experienced, naive) was not included
in the model as equally high proportions of patients were
ART naive. Follow-up time was greater in vertical programs
as these started earlier (2003) than integrated programs
(2005). The ﬁnal model included follow-up data censored at
30 months on ART.
Hazard proportionality was assessed by analysis of
scaled Schoenfeld residuals. The potential effect of mis-
classiﬁcation of mortality among patients lost to follow-up
was assessed in a sensitivity analysis using a competing risks
framework.
7 All reported P values are exact and 2-tailed, and
for each analysis, P less than 0.05 was considered signiﬁcant.
Ethics Statement
Ethical review and Individual patient consent were not
sought because the analysis was based on routine clinical
data. All patient information was entered into the database
using coded identiﬁcation numbers, and no information that
could reveal patient identity was included.
RESULTS
Baseline Characteristics
A total of 17,561 adult patients commenced ART in the
17 programs; 15,876 (90%) received treatment in 7 vertical
HIV programs, and 1685 (10%) in 10 integrated programs
(Table 2). Of these, 15,403 (88%) had at least 6 months of
follow-up time in the database and were included for analysis
of 12-month treatment outcomes, and 14,523 patients had
complete data for inclusion in the Cox proportional hazards
model. The number of patients per program ranged from 17 to
5029 (351 to 5029 for vertical, 17 to 480 for integrated).
Baseline characteristics differed by program design
(Table 3). Vertical programs had fewer female patients
(64% vs. 71%), and patients had an older median age (36.1
vs. 35.0), a higher body mass index (20.0 vs. 18.0), a lower
proportion of patients were classiﬁed clinical WHO stage
4 (18% vs. 36%), and fewer patients had a current TB dia-
gnosis (7% vs. 13%) at ART initiation (all P , 0.001). The
proportion of patients without prior exposure to ART at ini-
tiation with MSF was the same (94% vs. 94%).
Median CD4 was higher in integrated programs (150
vs. 132 for vertical programs), but CD4 measurement was not
administered uniformly: fewer patients overall had a CD4
measurement in integrated programs [61% (n = 781) vs. 70%
(n = 9833)], including a smaller proportion of patients in
WHO stage 4 [54% (n = 249) vs. 65% (n = 1606), P = 0.041].
Comparison of Outcomes With
Program Design
Median time on ART for all patients was 12.7 months
(interquartile range: 4.5–24.0) for vertical programs and 6.8
months (2.3–15.0) for integrated programs. After 12 months
on ART, the proportion of patients lost to follow-up was
similar for both program designs [11.8% (n = 1383) vs.
13.6% (n = 115) for vertical versus integrated programs res-
pectively, P = 0.12]; however, the proportion of patients who
had died was lower in vertical programs (7.9%, 929 patients
vs. 11.9%, 101 patients in integrated programs; P , 0.001).
In 6 vertical and 4 integrated programs, CD4 counts were
measured as follows: median gain in CD4 was not different
between program design after ART for either 6 months
(median CD4 gain 130 for vertical programs vs. 138 for
vertical for integrated programs; P = 0.11) or 12 months
(165 vs. 155; P = 0.83).
Multivariate risk analysis indicated that, converse to
a higher proportion of deaths at 12 months on univariate
analysis, the adjusted hazard of death was similar with both
program designs [Fig. 1, Table 4 adjusted hazard ratio (aHR):
1.02; 95% CI: 0.83 to 1.24]. Factors that were statistically
signiﬁcantly associated with mortality in the multivariable
model were increasing age, decreasing body mass index, clin-
ical WHO stage 4, and the age of the program at the time the
patient started ART. Having been diagnosed with clinical
WHO stage 4 gave the greatest risk for death (aHR: 1.99,
95% CI: 1.74 to 2.29), although being treated in a more
established program seemed to be protective (aHR: 0.77,
95% CI: 0.66 to 0.89). The integrated program design had
a signiﬁcantly lower risk for loss to follow-up (aHR: 0.71;
95% CI: 0.61 to 0.83), and most other signiﬁcant factors were
different to the outcome of death as follows: being treated in
a more experienced program was a risk for loss to follow-up
(aHR: 3.33; 95% CI: 2.92 to 3.79) and the greatest risk was
being in a rural setting (aHR: 3.83; 95% CI: 3.49 to 4.20).
The models did not display proportional hazards, so we
applied a range of statistical contingencies. Our mortality
estimate was unchanged in a competing risk regression (sub
hazard ratio: 1.03, 95% CI: 0.84 to 1.25), but the effect of
program design was somewhat sensitive to segmenting
follow-up time, with integrated programs being protective
for mortality in some 6 month periods.
DISCUSSION
Our study has demonstrated that patients managed in
integrated programs have similar or better outcomes when
compared with those managed in vertical HIV programs with
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validates the program design of integration and its associated
beneﬁts.
Although unadjusted estimates show a higher pro-
portion of deaths in integrated compared with vertical
programs, this is likely to be due to the fact that patients
were more clinically immunosuppressed at baseline in inte-
grated programs. Our Cox proportional hazards model
showed that with adjustment of other factors, the risk of
death up to 30 months after ART initiation was similar in
integrated compared with vertical programs and most signif-
icantly inﬂuenced by clinical WHO stage at ART initiation.
The risk of loss to follow-up in integrated programs was 29%
less than in vertical programs. These results may be explained
by better integration of services allowing more optimal
treatment of coexistent illness including TB (ie, treating the
patient holistically rather than treating an individual disease),
lower patient numbers allowing more individualized care and
follow-up, proximity of services allowing easier access for
patients, and a normalization of HIV reducing stigma and
increasing adherence to the program.
ART outcomes in both vertical and integrated pro-
grams are comparable to other published outcomes in
resource-limited settings. The Antiretroviral Therapy in
Lower Income Countries cohort of 18 programs in low-
income settings across Africa, Asia, and Latin America
reported 12-month combined mortality and lost-to follow-up
rates of 21% compared with 19% in MSF vertical and 24%
integrated programs in our study.
1 Furthermore, while not
measured in all patients, median immunological gains after
6 months of treatment seem slightly better in integrated and
vertical MSF programs compared with the Antiretroviral
Therapy in Lower Income Countries cohorts (138, 130,
and 106 cells/mm3, respectively).
TABLE 2. Location and Details of HIV Treatment Programs








Central African Republic Boguila Integrated Rural 2006 6.1% 184
Cote d’Ivoire Danane Integrated Rural 2005 4.8% 613
Democratic Republic of Congo Dubie Integrated Rural 2007 1.6% 95
Kilwa Integrated Rural 2007 1.6% 41
Walikale Integrated Rural 2006 1.6% 29
Dem. Rep. Congo (South Kivu) Baraka Integrated Rural 2006 1.6% 173
Bukavu Vertical Urban 2003 1.6% 1576
Ethiopia Abduraﬁ Vertical Rural 2007 — 396
Humera Vertical Rural 2004 — 894
Nigeria Lagos Vertical Urban 2004 3.7% 1918
Republic of Congo Kindamba Integrated Rural 2006 3.6% 23
Kinkala Integrated Rural 2005 3.6% 51
Mindouli Integrated Rural 2005 3.6% 222
Uganda Kitgum Integrated Rural 2007 6.3% 254
Zambia Nchelenge Vertical Rural 2003 14.1% 1250
Zimbabwe Epworth Vertical Urban 2006 17.2% 4336
Gweru Vertical Rural 2006 17.2% 5476
*HIV prevalence in year program ﬁrst provided ART.
TABLE 3. Baseline Characteristics at ART Initiation of Patients With at Least 6 Months of Follow-Up Time After Commencing ART,
by Program Design
Vertical (n = 14,124) Integrated (n = 1279) P
Female, n (%) 9056 (64%) 905 (71%) ,0.001
Age, median years (IQR) 36.1 (30.2–43.1) 35.0 (28.2–41.1) ,0.001
Body mass index, median (IQR) 20.0 (17.9–22.4) 18.0 (16.0–20.2) ,0.001
ART naive at ART initiation with MSF, n (%) 13267 (94%) 1202 (94%) 0.503
CD4*, median (IQR) 132 (63–199) 150 (66–224) 0.0009
Clinical WHO stage 4, n (%) 2489 (18%) 459 (36%) ,0.001
Clinical WHO stage 1–3, n (%) 11302 (82%) 818 (64%)
Current tuberculosis diagnosis, n (%) 997 (7%) 162 (13%) ,0.001
Program providing ART ,12 months when patient initiated ART, n (%) 2095 (15%) 535 (42%) ,0.001
Program in an urban setting, n (%) 6983 (49%) 0 (0%) ,0.001
*CD4 from up to 3 months before up until ART initiation available for 70% patients (n = 9833) in vertical programs and 61% (n = 781) in integrated.
IQR, interquartile range.
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integrated compared with vertical programs at ART initiation.
Notably, a higher proportion of patients were severely clinically
immunosuppressed (WHO clinical stage 4) in integrated
programs. This ﬁnding is similar to other reports
8 and likely
resulted from the fact that many of these programs targeted
people presenting to health facilities when they were already
sick, whereas vertical programs devoted speciﬁc resources to
large-scale community counseling and testing which attracts
more asymptomatic patients. The median CD4 count at ART
initiation was higher in integrated programs, but this was likely
due to the fact that a higher proportion of those in WHO stage 4
did not have a baseline CD4 count in integrated programs. This
may have occurred if CD4 count measurement was not done
when patients already qualiﬁed for ART based on clinical sta-
tus
9,10 and CD4 counts were instead reserved for those with
better clinical condition to guide ART initiation decisions.
Both program designs used similar inclusion criteria and
protocols for ART. The main difference was that in integrated
programs health staff tended to be less specialized and often
had a range of additional clinical and surgical duties (Table 1).
Simpliﬁcation of protocols took place mainly in terms of less
sophisticated laboratory monitoring and a more limited drug
formulary, in that some integrated programs had no access to
CD4 or biochemistry, and less choice of drugs for management
of opportunistic infections.
2,3 Integration of TB diagnosis and
treatment was the ambition for both program designs. Imple-
mentation of HIV care was taxing on the teams who were busy
with regular activities; however, we found that a standard pack-
age of protocols and training material helped staff, as did the
engagement of an experienced HIV clinician to help start the
program and train staff.
2 After adjusting for other factors in our
Cox hazards model, so irrespective of program design, the
longer time programs had been treating patients with ART
and thus the experience staff could have been expected to gain
was protective against death. On the other hand, program age
was a hazard for loss to follow-up, which we hypothesize
might indicate less time spent on patient selection, preparation,
and counselling for adherence to ART as the programs grow in
size. The substantially increased risk for loss amongst patients
treated in programs in rural settings is not surprising where
travel distances and transport options will be far more chal-
lenging than in urban settings.
Our study results demonstrate that integration of HIV
care into general medical services can be beneﬁcial in rural and
relatively low HIV prevalence settings. In a time of intense
debate regarding the merits of speciﬁc funding to HIV
services,
11 our data provides evidence in these settings that
resources dedicated to HIV through integrated programs can
beneﬁt the individual patient, and as we have previously des-
cribed, this can also strengthen the health system as a whole.
2,3
Our study is subject to several potential limitations.
First, it is important to note that the Cox hazards models did
not adhere to the assumption of proportional hazards, pri-
marily because of the body mass index variable which was
resistant to attempts to obtain proportionality through cate-
gorization, transformation, removal of data outliers, and
assessment of possible interactions. Nonetheless, it was
retained in the model as a clinically important factor related
to our outcomes of interest. The likely effect of a nonpropor-
tional predictor is that the power of the test for this variable is
reduced, such that any association may be missed, and the
concurrent model predictors that do satisfy proportionality
also suffer from decreased power associated with a poorer
overall model ﬁt.
12 A second potential limitation of the study
is the misclassiﬁcation of mortality among patients who were
lost to follow-up, as tracing has found that a proportion of
patients who are lost to care will have died.
13 However, the
results of our competing risks analysis suggested that such
misclassiﬁcation is not an important source of bias. Third,
there are substantially more patients in vertical than integrated
programs due to the focus and the timing of commencement
of programs; nonetheless, we were able to assess large num-
bers of patients treated in integrated programs. Furthermore,
vertical programs tended to be in larger and more urban faci-
lities, which may have had an unmeasured impact on out-
comes. Fourth, these data comes from a range of programs
across different countries and over a number of years, and
FIGURE 1. Cox proportional hazards regression plots of the
adjusted risk of (A) death and (B) loss to follow-up after initi-
ation of ART.
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quality may have varied between projects despite the use of
a standardized database. Although program protocols were
generally standardized and used the same drugs, training,
and advisors, there may be slight differences between pro-
grams in different contexts, and staff/patient ratios and clinical
workload were not measured. Thus, it is possible that any
unmeasured differences were not uniform between integrated
and vertical programs. However, after statistical assessment, it
was determined that clustering by program was not justiﬁed,
and in sensitivity analysis, it was found to negatively affect
hazard proportionality. Fifth, access to CD4 testing was limited
in some programs, and thus CD4 could not be included in the
Cox hazards model without losing too much data and poten-
tially biasing results. As there were signiﬁcant differences in
the groups between median CD4 at baseline, we are unable to
exclude this as having a signiﬁcant effect on the outcome.
Finally, the study will have had the expected limitations of
missing data and unmeasured confounders. However, our main
ﬁndings were unchanged by sensitivity analyses.
CONCLUSIONS
Integrated programs had good HIV treatment outcomes,
which are as good as or better than vertical programs,
particularly in terms of patient retention in care. This validates
the model of integrating HIV care into general medical
services to increase access to HIV services for populations
living in rural or lower HIV prevalence settings.
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